Press Releases

Jul 17, 2024

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Read More

Jun 03, 2024

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Read More

May 22, 2024

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

Read More

May 15, 2024

Veracyte to Participate in Upcoming Investor Conferences

Read More

May 07, 2024

Veracyte Announces First Quarter 2024 Financial Results

Read More

May 06, 2024

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Read More

Apr 22, 2024

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

Read More

Apr 22, 2024

New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Read More

Apr 16, 2024

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Read More

Feb 27, 2024

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

Read More